Skip to main content
. 2021 Apr 17;6(7):1829–1839. doi: 10.1016/j.ekir.2021.04.007

Figure 5.

Figure 5

Mean monthly i.v. iron use in roxadustat-treated patients (red) compared with epoetin alfa-treated patients (blue) was significantly reduced from baseline to week 52 (full analysis set).